Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.
Olivier AdotéviDewi VernereyPascale JacouletAurélia MeurisseCaroline LaheurteHamadi AlmotlakMarion JacquinVincent KaulekLaura BoullerotMarine MalfroyEmeline OrillardGuillaume EberstAurélie LagrangeLaure FavierMarie Gainet-BrunLudovic DoucetLuis TeixeiraZineb GhriebAnne-Laure ClairetYves GuillaumeMarie KroemerDidier HocquetMélanie MoltenisSamuel LimatElisabeth QuoixCéline MascauxDidier DebieuvreChristine Fagnoni-LegatChristophe BorgVirginie WesteelPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
UCPVax was highly immunogenic and safe and provide interesting 1-year OS rate in heavily pretreated advanced NSCLC.